Company intelligence / Profile preview

Zymtech Life Science

Norway

Ownership: Private
Development stage: Other

Overview

Company created and commercialized AMIZATE®, an enzymatic protein hydrolyzate derived from salmon, clinically validated and approved in several markets; used as a key active in branded functional health products such as Unbroken®.

Therapeutic areas: Metabolic DisordersOther
Modalities: ProteinPeptidesAmino acids
Industry: Food & Nutrition

Partnerships

Regulatory and distribution partnerships in US, EU, and Asia

Beyond the preview

Go deeper on Zymtech Life Science.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zymtech Life Science.

Explore the full profile